<DOC>
	<DOCNO>NCT00484094</DOCNO>
	<brief_summary>To provide safety effectiveness information Rapamune post-marketing period require Korea Food Drug Administration ( KFDA ) regulation order identify potential drug relate treatment factor Korean population , : 1 . Unknown adverse reaction , especially serious adverse reaction 2 . To assess incidence adverse reaction routine drug use 3 . Factors may affect safety drug ( e.g. , proteinuria ) 4 . Factors may affect effectiveness drug</brief_summary>
	<brief_title>Study Investigating Rapamune For Post-Marketing Surveillance</brief_title>
	<detailed_description>All patient receive Rapamune certain period time include far patient consent participate</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects age 13 year old receive renal transplant , newly administer Rapamune contract make Pfizer Korea investigator and/or institution conduct study . Any patient agree Pfizer company work Pfizer use his/her information . Patients know hypersensitivity Rapamune derivatives excipients formulation .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rapamune</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>